Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models

Journal of Gene Medicine

Volumn 10, Issue 6, 2008, Pages 690-701

  Fu, Wei ^a   Chu, Liang ^b   Han, Xinwei ^a   Liu, Xinyuan ^b   Ren, Daming ^a  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Apoptosis related; Cancer specific therapy; hTERT promoter; Orally attenuated S. typhimurium; Smac TRAIL; Synergistic effect

Indexed keywords

SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MELANOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA TYPHIMURIUM; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MITOCHONDRIAL PROTEINS; NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALMONELLA TYPHIMURIUM; TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VACCINES, ATTENUATED;

EUKARYOTA; MURINAE; MUS; SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA TYPHIMURIUM;

EID: 46649110349     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1191     Document Type: Article

References (33)

1. Sarkar D, Su Z-Z, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039.
2. Pawelek JM, Low KB, Bermudes D. Tumor-targeted S. typhimurium as a novel anticancer vector. Cancer Res 1997, 57: 4537-4544.
3. Low KB, Ittensohn M, Le T, et al. Lipid A mutant S. typhimurium with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
4. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-556.
5. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of S. typhimurium typhimurium. J Infect Dis 2000; 181: 1996-2002.
6. Steven A, Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated S. typhimurium. J Immunother 2002, 25: 218-225.
7. Saltzman DA, Katsanis E, Heise CP, et al. Antitumor mechanisms of attenuated S. typhimurium typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J Ped Surg 1997; 32: 301-306.
8. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573.
9. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002; 21: 656-663.
10. Gu J, Kagawa S, Takakura M, et al. Tumorspecific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359-5364.
11. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797-7803.
12. Gu J, Zhang L, Huang X, et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002; 21: 4757-4764.
13. Lin T, Huang X, Gu J, et al. Longterm tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020-8028.
14. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerasespecific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370-380.
15. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
16. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339-7348.
17. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16: 33-45.
18. Guo F, Nimmanapalli R, Paranawithana S, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2 I/ TRAIL-induced apoptosis. Blood 2002; 99: 3419-3426.
19. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2 I/TRAIL- or anticancer drug-induoed apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
20. Zifei Pei, Liang Chu, Weiguo Zou, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371-1381.
21. Theys J, Landuyt W, Nuyts S, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001; 8: 294-297.
22. Li X, Fu GF, Fan YR, et al. Bifidobacterium, adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111.
23. Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int J Med Microbiol 2004; 294: 319-335.
24. Brown SP, Cornell SJ, Sheppard M, et al. Intracellular demography and the dynamics of S. typhimurium enterica infections. PLoS Biol 2006; 4: E349.
25. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-320.
26. Lee C-H, Wu C-L, Shiau A-L. Endostatin gene therapy delivered by S. typhimurium choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382-1393.
27. Platt J, Sodi S, Kelley M, et al. Antitumour effects of genetically engineered S. typhimurium in combination with radiation. Eur J Cancer 2000; 36: 2397-2402.
28. Nakamura Y, Tahara E, Tahara H, Yasui W, Ide T. Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol Carcinog 1999; 26: 312-320.
29. Chiu CP, Dragowska W, Kim NW, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996; 14: 239-248.
30. Ramirez RD, Wright WE, Shay JW, Taylor RS. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol 1997; 108: 113-117.
31. Yasumoto S, Kunimura C, Kikuchi K, et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433-439.
32. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104: 10170-10174.
33. Agorio C, Schreiber F, Sheppard M, et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9: 416-423.